Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

16/25

Growth 5 Margin 4 Expansion 4 Platform 1 Financial 2

latest quarter score

Earnings Reports

16
Agios (AGIO) Q2 2026: 442 Akvesme Prescriptions Signal Broadening Thalassemia Penetration
July 30, 2026
16
Agios Pharmaceuticals (AGIO) Q4 2025: Pyruvate Kinase Franchise Revenue Jumps 86% as Thalassemia Launch Begins
June 15, 2026
14
Agios (AGIO) Q1 2026: Acvesme Scripts Jump 450% as Rare Disease Launch Outpaces Early Expectations
April 29, 2026
14
Agios (AGIO) Q3 2025: Pyruvate Kinase Franchise Grows 44% as Thalassemia and Sickle Cell Milestones Near
October 30, 2025
13
Agios (AGIO) Q2 2025: Pyruvate Kinase Franchise Revenue Jumps 45% as Thalassemia Launch Nears
July 31, 2025
12
Agios (AGIO) Q1 2025: $1.4B Cash War Chest Sets Up Dual Rare Disease Launches
July 04, 2025
Agios (AGIO) Q3 2024: $1.1B Milestone Fuels Thalassemia and Sickle Cell Launch Readiness
October 31, 2024
Agios (AGIO) Q2 2024: $905M Royalty Monetization Secures Launch Funding for Thalassemia and Sickle Cell Pipeline
August 01, 2024
Agios (AGIO) Q1 2024: Energize-T Data Readout Imminent as $714M Cash Fuels Multi-Indication Thrust
May 02, 2024
Agios (AGIO) Q4 2023: Energize Phase 3 Delivers 42% Response, Thalassemia Launch Path in Focus
February 15, 2024
9
Agios (AGIO) Q3 2023: $872M Cash Extends Runway as Six Late-Stage Readouts Approach
November 02, 2023
Agios (AGIO) Q2 2023: PK Activator Pipeline Delivers 20% Revenue Growth as Phase III Momentum Builds
August 03, 2023
Agios (AGIO) Q1 2023: Persistency Drives 14% Patient Growth as PK Activator Pipeline Hits Enrollment Milestones
May 04, 2023
Agios (AGIO) Q4 2022: 39% Patient Growth in Pyruvate Kinase Deficiency Sets Up Multi-Indication Expansion
February 23, 2023

Browse all companies